Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News FDA accepts review of Kala Pharmaceuticals’ new dry eye treatment KPI-121 0.25% The United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KPI-121 0.25%,… bypharmanewsdailyDecember 26, 2018